Penfluridol targets acid sphingomyelinase to inhibit TNF signaling and is therapeutic against inflammatory autoimmune diseases

BACKGROUND: Penfluridol, isolated from an FDA-approved small-molecule drug library as an inhibitor of tumor necrosis factor α (TNFα)-stimulated NF-κB activation, is clinically used to treat chronic schizophrenia and related disorders. This study is aimed to investigate the therapeutic effect of penf...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yue-hong, Liu, Rong-han, Cui, Ya-zhou, Hettinghouse, Aubryanna, Fu, Wen-yu, Zhang, Lei, Zhang, Chen, Liu, Chuan-ju
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8767691/
https://www.ncbi.nlm.nih.gov/pubmed/35045889
http://dx.doi.org/10.1186/s13075-021-02713-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8767691/
https://www.ncbi.nlm.nih.gov/pubmed/35045889
http://dx.doi.org/10.1186/s13075-021-02713-6

Ejemplares similares